NEW YORK (GenomeWeb News) – Laboratory Corporation of America is offering Roche's new Cobas AmpliPrep/Cobas TaqMan HCV test, which the US Food and Drug Administration cleared for marketing in October 2008.

The test is fully automated and uses Roche's proprietary real-time PCR technology to quantify the amount of virus in an individual's blood. Physicians can use it to monitor viral load at baseline and during treatment to help determine the effectiveness of therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.